glp-1 agonists in development A Closer Look at the Dermatological Profile of Evolution of GLP‐1 Receptor Agonists

Legal Disclaimer: Product images are for illustrative purposes only

SOURCE: Air Force SBIR Briefing for NRC Staff, June 2013

And more recently, further support has been provided by an analysis of a large medical database which suggests that GLP-1R agonist use may even reduce the risk of developing Parkinsons

Now, hes spotted an influx of peptides developed by ingredient manufacturers and ready to be dropped into new formulas

L-Carnitina L-Tartarato (LCLT): 1000-4000 mg

Mechanisms underlying neuroprotection include enhanced cerebral angiogenesis supporting tissue oxygenation, anti-inflammatory effects reducing secondary injury, antioxidant activity limiting free radical damage, and modulation of neurotransmitter systems including the dopamine/glutamate/NO system